RenovoRx (RNXT) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Verrica Pharmaceuticals (VRCA) over the past year, gaining 18.3% versus a loss of 34.9%. Over five years, RNXT leads with a -85.3% price change compared with -97.4% for VRCA. Verrica Pharmaceuticals is the larger company by market cap ($47.1 million vs $45.5 million), about 1.0 times the size, while RenovoRx is growing revenue faster (+2511.6% vs +370.2%).
Verrica Pharmaceuticals converts more of its revenue into profit, with a net margin of -50.3% versus -994.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNXT | VRCA |
|---|---|---|
| Share price | $0.942 | $2.74 |
| Market cap | $45.45M | $47.07M |
| 1-day change | -10.29% | -5.03% |
| YTD return | +12.14% | -67.03% |
| 1-year return | +18.34% | -34.92% |
| 5-year return | -85.26% | -97.38% |
| EPS (TTM) | $-0.31 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.12M | $35.58M |
| Revenue growth (YoY) | +2511.63% | +370.22% |
| Net income (latest FY) | $-11.17M | $-17.89M |
| Gross margin | 70.88% | — |
| Operating margin | -1113.98% | -34.25% |
| Net margin | -994.48% | -50.27% |
| 52-week high | $2.59 | $9.82 |
| 52-week low | $0.77 | $2.73 |
| Distance from 52-week high | -63.63% | -72.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +656.90% | +404.74% |
| Average volume | 815.75K | 68.78K |
| Shares outstanding | 48.25M | 17.18M |
| Employees | 17 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed VRCA by 53.3 percentage points over the past year.
- Verrica Pharmaceuticals is more profitable, keeping -50.3 cents of every revenue dollar as net income versus -994.5 cents for RenovoRx.
- RenovoRx grew revenue faster in its latest fiscal year (+2511.63% vs +370.22%).
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
RNXT vs VRCA FAQ
Which is bigger, RenovoRx or Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $47.07M compared with $45.45M for RenovoRx (RNXT).
Which stock has performed better over the past year, RNXT or VRCA?
RNXT returned +18.34% over the past 12 months, compared with -34.92% for VRCA (price return, excluding dividends). Past performance does not predict future results.
Are RenovoRx and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.